19:21 , Jun 20, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Cell therapy A method utilizing click chemistry to generate injectable hydrogels containing cross-linked cells could be used in regenerative therapies. The method generates hydrogels containing cross-linked cells in three steps: metabolic incorporation of azide groups...
15:30 , Jun 8, 2018 |  BC Week In Review  |  Company News

DRC approves compassionate use of investigational Ebola treatments

A Democratic Republic of the Congo ethics committee approved the use of five investigational Ebola therapies under compassionate use and expanded access. The World Health Organization said four of the five approved products are in the...
21:03 , Jun 6, 2018 |  BC Extra  |  Company News

DRC approves investigational Ebola treatments

A Democratic Republic of the Congo ethics committee approved the use of five investigational Ebola therapies under compassionate use and expanded access. The World Health Organization said four of the five approved products are in the...
23:43 , May 31, 2018 |  BC Extra  |  Company News

Regeneron sends experimental Ebola therapy to Congo

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said it began shipping its investigational Ebola antibody cocktail REGN-EB3 (REGN3470-3471-3479) to the Democratic Republic of the Congo (DRC). REGN-EB3 was one of several experimental therapies considered for the treatment of Ebola...
18:23 , May 25, 2018 |  BC Week In Review  |  Company News

WHO to start treatment with Merck's Ebola vaccine

The World Health Organization began administering Ebola vaccine rVSV-ZEBOV (V920) from Merck & Co. Inc. (NYSE:MRK) on May 21 in two cities in the Democratic Republic of the Congo (DRC). Vaccination will be administered using...
23:03 , May 18, 2018 |  BC Extra  |  Politics & Policy

WHO: Congo may approve mAb Zmapp for Ebola outbreak

The Democratic Republic of the Congo is likely to approve the use of Zmapp “in the coming days” to treat patients affected by the country's Ebola outbreak, the World Health Organization said Friday. President Larry...
18:32 , May 15, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Binding assays; cellular assays A click chemistry-based method for identifying cell surface glycoproteins that bind orphan ligands could help identify new therapeutic targets. The method involves three steps: mildly oxidizing live cells to produce aldehyde...
15:04 , Apr 9, 2018 |  BC Extra  |  Preclinical News

Targeting neuraminidase could improve flu vaccine

A paper in Cell proposes a new strategy to develop an influenza vaccine exploiting the less targeted surface glycoprotein neuraminidase. Efforts to produce effective influenza vaccines have mainly focused on inhibiting hemagglutinin, the more abundant of...
23:20 , Dec 14, 2017 |  BC Innovations  |  Product R&D

Opening doors in PML

An NIH-led team has demonstrated that neutralizing antibodies can prevent infection of cells by mutant strains of JCV -- the virus responsible for the lethal brain infection PML. In a field with no clinical options,...
21:54 , Dec 1, 2017 |  BC Week In Review  |  Company News

BARDA awards $170.2M for Ebola vaccines

HHS’s Biomedical Advanced Research and Development Authority (BARDA) awarded four contracts totalling $170.2 million to fund late-stage development and purchase of Ebola vaccines. Merck & Co. Inc. (NYSE:MRK) will receive $39.2 million to develop its single-shot...